-
Series serialization| Overseas wayfinding, the next decade of China's local pharmaceutical companies (1)
Time of Update: 2023-01-05
) ）GBI (click to read)"Combo punch" attack: overseas mode and market selectionInspiration and reflection: a voyage that "opens up a different way"As the first part of this series, this article will analyze the drivers and trends of innovative pharmaceutical companies going global.
-
Latest! Forecast of the 8th batch of nationally harvested varieties (with list of enterprises)
Time of Update: 2023-01-05
Attached: Forecast of the eighth batch of nationally harvested varietiesAttached: Forecast of the eighth batch of nationally harvested varieties Source: Yilian Recruitment Network In terms of rules, the industry has also called for certain changes.
-
When is the downturn going on? Three ways to help pharmaceutical companies withstand the "cold winter"
Time of Update: 2023-01-05
3 ways pharma can weather a recession； pharmavoice Increased product sales and deals can only partially shield pharmaceutical companies from the winds of a harsh recession, rather than focus on reducing costs, especially at a time of rising inflation.
-
The FDA Commissioner talks to the Director of the Oncology Center of Excellence to discuss several hot topics
Time of Update: 2023-01-05
[1] The Commissioner of the FDA and the Director of the Oncology Center of Excellence comment on hot regulatory topics[2] The Center for Drug Evaluation of the State Food and Drug Administration of Ch
-
The Swing of Azvudine: Between Lianhua Qingwen and Paxlovid
Time of Update: 2023-01-05
As a soon-to-be-listed company, the first test of commercialization is so broken -02- -02-Behind the Stop keyBehind the Stop keyIn fact, in July this year, consumers also found in the mini program of an online pharmacy that another approved new crown oral drug Pfizer P drug in China was on the shelves.
-
This biotech with "only 6 full-time employees" is about to IPO, can it be more "small and beautiful"?
Time of Update: 2023-01-05
com/） Company official website Company official website #EXECUTIVE_DIRECTOR_COMPENSATION #EXECUTIVE_DIRECTOR_COMPENSATION Other publicly available information Other publicly available information Since disease treatment entered the era of immunotherapy, T cells have become the focus of new drug developers, if the definition of "target" is expanded, T cells will undoubtedly be the hottest target in the past 20 years.
-
Yuan Jianwei: In the next journey of innovative drug investment, we must first be clear about "whose money you want to make"
Time of Update: 2023-01-05
Yuan Jianwei:Vertex Ventures China Fund China) In 2008, it began to make China's technology investment, and in 2013, in the era of vigorous Internet e-commerce, Vertex instead laid out a lithium metal battery start-up company SES, when the public was not very clear about the future of lithium metal batteries, Vertex has in-depth research and forward-looking judgment on the development of the new energy industry, and attaches great importance to the founder's deep technical accumulation in this project.
-
Chinese pharmaceutical companies have accelerated their overseas expansion, and a number of new drug clinical applications have been accepted by the FDA
Time of Update: 2023-01-05
At present, the overseas expansion of Chinese pharmaceutical companies continues to accelerate, and affected by this, it has recently been reported that a number of domestic new drug clinical trial applications have been accepted by the FDA.
-
In order to cultivate medical talents, various localities are actively issuing favorable measures
Time of Update: 2023-01-05
At present, in order to further promote the innovation and development of the domestic pharmaceutical industry and provide a stronger talent guarantee, relevant favorable documents and measures are continuously issued from the country and even all localities to vigorously cultivate pharmaceutical talents.
-
The orthopedic market is attracting attention, and another new drug may be launched
Time of Update: 2023-01-05
For example, in July, Kanghe Biotherapeutic Biological Products Class 1 new drug injection K11 was implicitly approved by the State Food and Drug Administration for clinical trials, and is intended to be used for the treatment of degenerative cartilage wear lesions, osteoarthritis and other diseases.
-
How to deal with the most common cancers in the world? Please collect this list
Time of Update: 2023-01-05
The US FDA approved it as an extended adjuvant therapy for patients with HER2-positive early-stage breast cancer, and in 2020 further expanded its indication to combine the chemotherapy drug capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have previously received at least 2 anti-HER2 regimens.
-
A full inventory of domestic gene therapy companies
Time of Update: 2023-01-05
Global gene therapy has started, in recent years, domestic gene therapy companies have appeared frequently, what stage has domestic gene therapy developed? We studied the basic situation of more than
-
ADC new drug R&D pattern in China
Time of Update: 2023-01-05
As of November 2022, NMPA has accepted a total of 80 new ADC drugs. Since 2020, the research and development of new ADC drugs in China has become popular and has entered a stage of explosive growth, w
-
Wanchun Pharmaceutical: Received a warning from NASDAQ for delisting
Time of Update: 2023-01-05
summary On November 23, 2022, Wanchun Pharmaceutical announced that it had received a written delisting warning from NASDAQ on November 18, as its share price fell below the minimum requirement of US$1 per share for 30 consecutive trading days.
-
Changes in the new crown oral drug market: the generic version of Pfizer Paxlovid has entered the clinic
Time of Update: 2023-01-05
A search of the "China Clinical Trials Registry" website shows that CSPC registered the bioequivalence trial of nematevir tablets on September 26, 2022According to the trial registration information, the purpose of the trial is to evaluate the nematevir tablets and Pfizer Manufacturing Deutschland produced by Sinopharma Pharmaceutical Group Bioequivalence of the reference preparation nematevir tablets produced by GmbH.
-
Next year's pharmaceutical bull market?
Time of Update: 2023-01-05
Domestic substitution + innovation and upgrading + policy-side financial support, the high prosperity of the medical device industry will continue, and it will also become one of the core main lines of future pharmaceutical investment.
-
Latest! The "Fudan Version" hospital ranking was released
Time of Update: 2023-01-05
Source: China Health, Institute of Hospital Management, Fudan University, Pharmaceutical Cloud Studio This is the thirteenth consecutive release of the Fudan version of the Chinese Hospital Ranking.
-
After the approval of the first hemophilia B gene therapy, how has global gene therapy progressed? Read it all over in one article!
Time of Update: 2023-01-05
Yesterday, the world's first hemophilia B gene therapy Hemgenix (etranacogene dezaparvovec) received FDA approval. Hemgenix is owned by CSL Behring developed a gene expressing the coagulation factor I
-
Song Ruilin, Executive President of the China Association for the Promotion of Medicine: China's pharmaceutical innovation is entering the 2.0 era
Time of Update: 2023-01-05
Since the 18th National Congress in 2016, it has been proposed that China's future development should be driven by scientific and technological innovation. So far, the 20th National Congress of the Co
-
Biotech stocks are on a roller coaster, but they continue to outperform!
Time of Update: 2023-01-05
Figure 2 Part of the product pipeline (Source: Genmab official website)In the third quarter of September, earnings and sales grew strongly to 53 cents per share and $551 million, respectively.
